It was Round 2 of raids against vape shops in Westmoreland ... The effort came on the heels of Thursday’s raids by authorities at Vape and Smoke City in Hempfield, EZ Tobacco and Vape in Delmont ...

Shuffield’s husband took a puff of his vape and blew it down onto the floorboards. As he puffed out the light plume of smoke, the filter’s interior ... PM2.5 (aka particulate matter with a diameter of ...

The raids took place at EZ Tobacco & Vape in Delmont, Vape & Smoke City in Hempfield and The Vape EXcape in Latrobe. It was a joint effort by local and state police, as well as Westmoreland County ...

“EZ Tobacco and Vape” in Delmont, “Vape and Smoke” in Hempfield Township and “The Vape Escape” in Latrobe are all accused of selling illegal products or legal products to underage buyers.

It will be illegal for anyone currently aged 15 or under to ever buy cigarettes in the UK, under new laws proposed by the government. The plan is part of a series of measures aimed at tackling the ...

Novo Nordisk has successfully concluded a share repurchase program initiated on August 7, 2024, buying back B shares worth DKK 2.4 billion. This initiative is part of a larger plan to repurchase ...

While the deal would not weigh heavily on Roche’s own production operations, “it could be a problem for other smaller players if there is a restriction in terms of how many CMOs are available ...

Last year, Novo Nordisk’s subcutaneous once-weekly (injectable) semaglutide 2.4 mg, available as Wegovy, showed a 20% reduction in MACE compared to placebo. The SOUL trial compared oral ...

Oral semaglutide, sold as Rybelsus, reduced the risk of a group of cardiovascular events by 14% compared with placebo in certain patients with Type 2 diabetes in a late-stage study, Novo said Monday.

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes ...

The study tested the drug as an adjunct to standard of care in 9,650 patients with type 2 diabetes and established cardiovascular disease and/or chronic kidney disease, the company said.